Davunetide: A Literature Course on the Published Evidence

Davunetide, also written as NAP, is one of the more thoroughly documented neuroprotective peptide candidates of the past two decades. It moved from cell culture through rodent models into human trials, and the results — including a large negative phase 2/3 trial — are all in the public literature. This page is a reading course: six modules that describe what researchers did, what they measured and what they reported, followed by an explicit list of questions the published studies did not address.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no outcome described below should be read as a promise of benefit.

Module 1: What Davunetide Is and How It Has Been Studied

Definition, class and origin

Davunetide is a short synthetic peptide of eight amino acids, NAPVSIPQ, which is why it is commonly abbreviated NAP; review articles describe it as the active fragment of activity-dependent neuroprotective protein (ADNP), a protein identified in the brain and described as essential for brain formation (PMID 24533805). Its pharmacological class, as characterised in the peptide literature, is a microtubule-interacting neuroprotective peptide rather than a hormone, growth factor or receptor agonist (PMID 24210139).

Forms studied

Reviews of the development programme describe two routes of administration used in human studies — an intranasal formulation and a systemic (intravenous) formulation — with the intranasal route selected to exploit nose-to-brain delivery (PMID 23971871). A 2025 review specifically examined intranasal NAP in relation to neuroprotection and circadian rhythmicity, indicating that the intranasal form remained the focus of continuing academic interest (PMID 40185278). Systemic administration was the format studied in the coronary artery bypass grafting (CABG) setting (PMID 41173865).

How it has been studied

• In vitro work — neuronal and glial cultures used to test protection against toxic insults and to characterise microtubule effects (PMID 21524250).
• Genetic and lesion rodent models — including ADNP-deficient mice used in the preclinical schizophrenia programme (PMID 21050875).
• Tauopathy and Alzheimer's-associated models — behavioural endpoints in rats and tau-focused molecular work (PMID 28257938, PMID 30865715).
• Human trials — a randomised, double-blind, placebo-controlled phase 2/3 study in progressive supranuclear palsy (PSP) (PMID 24873720), plus later re-analyses of earlier trial datasets in prodromal Alzheimer's disease and in cardiac surgery (PMID 39358355, PMID 41173865).

Limits of the evidence in Module 1

The descriptive literature is dominated by reviews written by groups closely associated with the peptide's discovery, which means the framing of its promise is not independent of its developers. Abstract-level sources also do not provide a full inventory of formulation details, excipients or manufacturing specifications, so "davunetide" in one paper is not automatically identical in purity or presentation to material described elsewhere.

Module 2: Mechanism as Described in the Literature

Microtubules and axonal transport

The central mechanistic claim across the review literature is that davunetide acts on microtubules — the intracellular scaffolding that supports axonal transport — and that this stabilising action underlies the protection observed in models (PMID 24210139). A 2011 review summarised the functional and structural neuroprotection attributed to NAP in cell and animal systems and linked it to microtubule integrity rather than to a classical receptor pathway (PMID 21524250).

Tau as the proposed target

A second line of work proposed tau-associated microtubule dynamics as the therapeutic target, with reviewers describing NAP in the context of tauopathies rather than amyloid biology (PMID 21902667). A 2019 laboratory study reported that NAP interacted preferentially with dynamic 3-repeat tau, and the authors used that selectivity to explain why protection appeared in some tauopathy contexts and not others (PMID 30865715). That paper is important for interpreting the negative PSP trial, because PSP is predominantly a 4-repeat tauopathy.

Additional mechanisms described

Preclinical schizophrenia work described microtubule deficits associated with reduced ADNP and reported that NAP treatment affected cognitive behaviour in those models, which the authors framed as evidence for a microtubule-cognition axis (PMID 21050875). More recently, a review raised circadian rhythmicity as an additional dimension of intranasal NAP biology, alongside neuroprotection (PMID 40185278).

Limits of the evidence in Module 2

Mechanistic accounts rest largely on in vitro systems and genetically modified rodents. A mechanism that is demonstrable in a dish or in a knockout mouse does not establish that the same mechanism operates at achievable human exposures, and the tau-isoform selectivity reported in 2019 came after the pivotal human trial had already been conducted — mechanism was, in this programme, partly reconstructed from a failure rather than predicting success.

Module 3: Reported Outcomes by Study

The phase 2/3 PSP trial

The largest human dataset is a randomised, double-blind, placebo-controlled phase 2/3 trial in progressive supranuclear palsy that assigned 313 participants to intranasal davunetide 30 mg twice daily or placebo for 52 weeks and used the PSP Rating Scale and the Schwab and England Activities of Daily Living scale as co-primary endpoints (PMID 24873720). The investigators reported no significant difference between davunetide and placebo on the primary endpoints, and concluded that the results did not support efficacy in PSP (PMID 24873720).

Re-analyses reporting sex-dependent findings

A 2024 analysis of clinical data in prodromal Alzheimer's disease reported that davunetide's effect on memory measures was sex-dependent, with the benefit described by the researchers as concentrated in one sex rather than in the pooled population (PMID 39358355). A 2025 paper applied similar reasoning to systemic davunetide in the setting of coronary artery bypass grafting and again reported sex-specific neuroprotective findings (PMID 41173865). Both are secondary, sex-stratified analyses rather than trials designed and powered in advance to test a sex-by-treatment interaction.

Animal behavioural outcomes

A 2017 rodent study reported that davunetide improved spatial learning and memory performance in rats modelling Alzheimer's-disease-associated deficits (PMID 28257938). Earlier preclinical work in the schizophrenia programme reported effects of NAP on cognitive behaviour in models featuring microtubule and ADNP deficits (PMID 21050875), and a review of the broader preclinical record described both functional endpoints and structural markers of neuroprotection (PMID 21524250).

Limits of the evidence in Module 3

The one adequately sized, prospectively designed efficacy trial was negative on its co-primary endpoints (PMID 24873720). The sex-stratified findings published a decade later are hypothesis-generating: subgroup analyses of existing datasets carry a higher risk of chance findings and have not been confirmed in a dedicated prospective trial. Rodent behavioural improvements have historically translated poorly to human cognition endpoints, and the rodent papers here do not establish human efficacy.

Module 4: Davunetide Side Effects: What Studies Report

What the published safety record contains

The most informative human safety dataset is the phase 2/3 PSP trial, in which 313 participants received intranasal davunetide 30 mg twice daily or placebo for 52 weeks — a year of continuous exposure in an older, neurologically impaired population (PMID 24873720). A dedicated review of safety and efficacy data with a focus on neurodegenerative diseases summarised the clinical experience available at that time and characterised davunetide as having been well tolerated across the studies it covered (PMID 23971871). A separate review of davunetide as a peptide therapeutic in neurological disorders likewise described a tolerability profile that permitted progression into later-phase testing (PMID 24533805).

Route-related considerations described in the literature

Because the clinical programme relied heavily on intranasal delivery, the reviews discuss nose-to-brain administration as the defining feature of exposure, and a 2025 review continued to treat the intranasal route as central to the peptide's profile (PMID 40185278). Intranasal delivery in general is associated with local nasal effects, and the published reviews of davunetide discuss the route rather than presenting itemised event-by-event tables (PMID 23971871).

What is not in the published safety record

• No abstract-level source in this course provides a complete, itemised adverse-event table with incidence rates by organ system.
• No study described here evaluated exposure beyond one year, so long-term safety is unaddressed (PMID 24873720).
• The reviews summarising tolerability were authored within the research community that developed the peptide, which is relevant to how "well tolerated" should be weighted (PMID 23971871, PMID 24533805).

Limits of the evidence in Module 4

"Well tolerated" in a supervised trial of a defined formulation, at a defined dose, in a defined population is a narrow statement. It says nothing about unsupervised use, other routes, other doses, other populations, pregnancy, paediatric exposure, or interactions with concurrent medications. Rare events would not be detectable in a study of this size, and non-clinical-grade material is not represented anywhere in this literature.

Module 5: Pharmacokinetics Where Data Exist

Pharmacokinetic description of davunetide in the accessible literature is qualitative rather than numerical. Reviews describe the rationale for intranasal administration as achieving central nervous system exposure of a small peptide, with nose-to-brain transport presented as the delivery strategy (PMID 40185278). The safety and efficacy review discusses the clinical development of both intranasal and systemic presentations, indicating that different exposure profiles were pursued for different indications (PMID 23971871), and the CABG analysis addressed systemic rather than intranasal administration (PMID 41173865).

Mechanistic reviews also note that NAP activity was demonstrated in cell systems at very low concentrations, which was part of the argument that small delivered quantities might suffice for central effects (PMID 21524250). The only human dosing regimen described in a controlled efficacy setting in this course is intranasal 30 mg twice daily over 52 weeks (PMID 24873720).

Limits of the evidence in Module 5

No half-life, maximum concentration, time to maximum concentration, bioavailability percentage or clearance value is presented here, because those figures are not available from the abstract-level sources in this course. Peptides of this size are generally subject to rapid enzymatic degradation, and the absence of published human concentration–time data means the relationship between an administered quantity and brain exposure remains poorly quantified in the public record.

Module 6: Regulatory Status

Davunetide is not an approved drug product. There is no marketing authorisation for it in the United States or the European Union for any indication, and the pivotal phase 2/3 trial in progressive supranuclear palsy reported that the drug did not separate from placebo on its co-primary endpoints, a result that ended the programme's late-stage momentum (PMID 24873720). Subsequent publications have been academic re-analyses and reviews rather than new registration trials (PMID 39358355, PMID 41173865).

Practically, this means:

• Research-use-only status. Material labelled davunetide or NAP is supplied for laboratory research. Research-use-only material is not manufactured, tested or labelled as a medicine for human administration.
• Not a dietary supplement. A synthetic peptide of this kind does not meet the definition of a dietary ingredient in the United States, so it cannot lawfully be marketed as a supplement.
• Compounding. In the United States, pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may compound only from substances that meet defined statutory criteria — generally components of approved drugs, substances with a USP monograph, or substances appearing on the applicable FDA bulk drug substance lists. A peptide with no approved product and no monograph does not satisfy those criteria.
• Sport. Anti-doping status is determined by the World Anti-Doping Agency Prohibited List and its annual revisions; athletes subject to testing are governed by that list rather than by research literature.

This regulatory summary is general information and is not legal advice; rules differ by country and change over time.

Limits of the evidence in Module 6

Regulatory status is a statement about legal and administrative categories, not about biology. The fact that a compound has been studied in a phase 2/3 trial does not make it approved, and the fact that it failed a primary endpoint in one tauopathy does not, by itself, close every scientific question about the molecule — as the later tau-isoform work illustrates (PMID 30865715).

What the Studies Did Not Test

Reading the whole set together, several gaps are conspicuous:

1. Healthy-person cognition. Every human study described here enrolled patients — PSP, prodromal Alzheimer's disease, cardiac surgery (PMID 24873720, PMID 39358355, PMID 41173865). None tested cognitive enhancement in healthy adults.
2. Prospective confirmation of the sex-dependent findings. The sex-stratified results were reported from existing datasets, not from trials designed in advance to test them (PMID 39358355).
3. Exposure beyond a year. The longest controlled human exposure described is 52 weeks (PMID 24873720).
4. Head-to-head comparisons. No study here compared davunetide with another microtubule-directed agent, despite reviews discussing that broader class (PMID 24210139).
5. Quantitative human pharmacokinetics. The accessible record does not supply concentration–time parameters, so dose–exposure–response relationships remain unresolved (PMID 23971871).
6. Non-pharmaceutical material. Every result described came from material prepared for controlled research or clinical use; nothing in this literature characterises products of unknown provenance.

Davunetide is, in short, a well-documented example of a mechanistically attractive peptide that did not confirm its clinical hypothesis in the one large trial designed to test it, and whose story continued afterwards as mechanistic and subgroup science (PMID 24873720, PMID 30865715). That combination is exactly why the individual study details matter more than any summary label.

References

• Davunetide: Peptide therapeutic in neurological disorders (Current Medicinal Chemistry, 2014)
• Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases (Expert Review of Clinical Pharmacology, 2013)
• Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP) (Neuropeptides, 2013)
• Davunetide sex-dependently boosts memory in prodromal Alzheimer's disease (Translational Psychiatry, 2024)
• Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity (Advanced Drug Delivery Reviews, 2025)
• Systemic davunetide provides sex-specific neuroprotection during Coronary Artery Bypass Grafting (CABG) (Translational Psychiatry, 2025)
• Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate (Peptides, 2011)
• NAP (davunetide) provides functional and structural neuroprotection (Current Pharmaceutical Design, 2011)
• Microtubules (tau) as an emerging therapeutic target: NAP (davunetide) (Current Pharmaceutical Design, 2011)
• Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats (Physiology & Behavior, 2017)
• NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies (PLoS One, 2019)
• Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial (The Lancet Neurology, 2014)